PANCREATIC S2001

Randomized Phase II Clinical Trial of Olaparib + Pebrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Back To Clinical Trials NCI Database Entry